ORIC

Oric Pharmaceuticals, Inc. (ORIC) | Rumor.io

Oric Pharmaceuticals

ORIC

Attention (50-day avg)0%

Attention rank (50-day avg)#2,686

Bullish sentiment (50-day avg)82%

Price to earnings ratio-9.03

Market capitalization1.4B

Earnings per share-1.3

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-129.5M

Social

What share of all stock conversation is about ORIC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Apr 2

ORIC Pharmaceuticals is being considered for a potential acquisition by Citi, with some investors suggesting it's a "safe bet" compared to other tech stocks.
Analysts are reiterating a buy rating on ORIC, with one investor expecting a price target of $9 and another anticipating a quick spike to $14 in the next few days.
The company's recent bounce from oversold conditions has been attributed to its potential best-in-disease profile, with one investor noting a significant increase in price of 10.64% on a specific date.

Generated by AI

Sentiment

Of the messages about ORIC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +33.33	89.76% -1.52
Bearish	—	—	0% -33.33	10.24% +1.52

Bullish· Apr 1

$ORIC is considered a "best in class" asset with a favorable efficacy and tolerability profile, making it an attractive buy.
The company's stock is undervalued, presenting a buying opportunity, especially with a potential rebound from its current oversold state.
Analysts and investors are bullish on ORIC Pharmaceuticals, with some expecting a significant price increase once the stock breaks above $9.14.

Bearish· Apr 1

The company's stock has been heavily sold off, with some users mentioning selling at $12.5 and others stopping out at $7.50.
The stock's price action has been described as "disgusting" and "a mess", with some users expecting further declines.
The company's trial update, specifically the selection of a lower 400 mg dose of its investigational drug, has been cited as a reason for the stock's decline.

Generated by AI

Topics

Of the messages about ORIC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	88.84%
Technical Analysis	—	0%	0%	6.61%
Analysts	—	0%	0%	4.44%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0.11%

Announcements· May 28

ORIC Pharmaceuticals has secured a $125 million private placement financing led by SR One, with participation from various institutional investors.
The company has announced potentially best-in-class preliminary efficacy and safety data from its ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
The trial showed a 59% PSA50 response rate and a 24% PSA90 response rate across all dose levels, with most patients still ongoing on therapy.

Technical Analysis· Feb 9

ORIC Pharmaceuticals has a large-cap biotech play with multiple bottoms on the daily chart and a golden cross on 2/4/21.
The 5-minute chart for ORIC shows a golden cross, a bullish signal.
ORIC has a potential price target of $39.40 with a stop-loss at $28.90.

Generated by AI

Community

Of the messages about ORIC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	29.41%	37.71%
Newcomers	—	0%	70.59%	62.29%

Regulars· Mar 16

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates, with GAAP EPS of -$0.52 beating estimates by $0.02.
Oppenheimer upgrades ORIC Pharmaceuticals to Outperform from Perform, setting a $14 price target.
ORIC Pharmaceuticals files form 8-K and form 10-K, disclosing fourth quarter and full year 2022 financial results, including GAAP EPS of -$2.25.

Newcomers· Apr 2

Wainwright & Co. maintains a buy recommendation and $25 price target for ORIC Pharmaceuticals, despite recent stock declines.
New investors are concerned about ORIC's reliance on intangibles and limited reinvestment opportunities, leading to stock price drops.
Disappointing early-stage prostate-cancer trial results have caused a significant decline in ORIC Pharmaceuticals' stock price, with some analysts reacting negatively.

Generated by AI

News

Oric Pharma CFO sells $181k in shares

12h agoInvesting.com

H.C. Wainwright raises ORIC Pharmaceuticals price target to $27 on pipeline progress

1mo agoInvesting.com

Tracking Ole Andreas Halvorsen’s Viking Global Portfolio – Q1 2026 Update

2mo agoSeeking Alpha

ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen Bull Case (NASDAQ:ORIC)

2mo agoSeeking Alpha

ORIC Pharmaceuticals initiates phase 3 prostate cancer trial

2mo agoInvesting.com

Also Discussed

Investors talking about ORIC also mention

#	Name	Attention
1	Pharvaris N.V. Ordinary SharesPHVS	0%0
2	MRTX - Mirati Therapeutics, Inc.	——
3	OMIC - Singular Genomics Systems, Inc.	——
4	Nurix Therapeutics, Inc.NRIX	0%new
5	ICVX - Icosavax, Inc.	——
6	Gossamer Bio Inc.GOSS	0%+0
7	CNTA - Centessa Pharmaceuticals plc	——
8	Janux Therapeutics, Inc.JANX	0%0
9	Biomea Fusion Inc.BMEA	0.01%-0.01
10	TERN - Terns Pharmaceuticals, Inc.	——

Oric Pharmaceuticals, Inc.

Healthcare
Biotechnology

Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies that address resistance to treatment. The company’s research pipeline centers on precision oncology, hormone-dependent cancers, and key tumor dependencies, with current programs designed to target mechanisms that limit the effectiveness of existing cancer medicines. Its product candidates include therapies in clinical development for genetically defined cancers and prostate cancer, along with additional discovery-stage oncology programs. Oric Pharmaceuticals operates as a single business segment and concentrates its efforts on advancing research, clinical development, and translational science for cancer treatment. The company is headquartered in South San Francisco, California, with additional operations supporting its development work in the United States. Its role in the market is to contribute experimental oncology candidates to the broader pipeline of targeted cancer therapeutics.

Website

Location

240 E. Grand Ave

South San Francisco, CA, 94080

United States

Social

What share of all stock conversation is about ORIC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Apr 2

ORIC Pharmaceuticals is being considered for a potential acquisition by Citi, with some investors suggesting it's a "safe bet" compared to other tech stocks.
Analysts are reiterating a buy rating on ORIC, with one investor expecting a price target of $9 and another anticipating a quick spike to $14 in the next few days.
The company's recent bounce from oversold conditions has been attributed to its potential best-in-disease profile, with one investor noting a significant increase in price of 10.64% on a specific date.

Generated by AI

Sentiment

Of the messages about ORIC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +33.33	89.76% -1.52
Bearish	—	—	0% -33.33	10.24% +1.52

Bullish· Apr 1

$ORIC is considered a "best in class" asset with a favorable efficacy and tolerability profile, making it an attractive buy.
The company's stock is undervalued, presenting a buying opportunity, especially with a potential rebound from its current oversold state.
Analysts and investors are bullish on ORIC Pharmaceuticals, with some expecting a significant price increase once the stock breaks above $9.14.

Bearish· Apr 1

The company's stock has been heavily sold off, with some users mentioning selling at $12.5 and others stopping out at $7.50.
The stock's price action has been described as "disgusting" and "a mess", with some users expecting further declines.
The company's trial update, specifically the selection of a lower 400 mg dose of its investigational drug, has been cited as a reason for the stock's decline.

Generated by AI

Topics

Of the messages about ORIC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	88.84%
Technical Analysis	—	0%	0%	6.61%
Analysts	—	0%	0%	4.44%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0.11%

Announcements· May 28

ORIC Pharmaceuticals has secured a $125 million private placement financing led by SR One, with participation from various institutional investors.
The company has announced potentially best-in-class preliminary efficacy and safety data from its ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
The trial showed a 59% PSA50 response rate and a 24% PSA90 response rate across all dose levels, with most patients still ongoing on therapy.

Technical Analysis· Feb 9

ORIC Pharmaceuticals has a large-cap biotech play with multiple bottoms on the daily chart and a golden cross on 2/4/21.
The 5-minute chart for ORIC shows a golden cross, a bullish signal.
ORIC has a potential price target of $39.40 with a stop-loss at $28.90.

Generated by AI

Community

Of the messages about ORIC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	29.41%	37.71%
Newcomers	—	0%	70.59%	62.29%

Regulars· Mar 16

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates, with GAAP EPS of -$0.52 beating estimates by $0.02.
Oppenheimer upgrades ORIC Pharmaceuticals to Outperform from Perform, setting a $14 price target.
ORIC Pharmaceuticals files form 8-K and form 10-K, disclosing fourth quarter and full year 2022 financial results, including GAAP EPS of -$2.25.

Newcomers· Apr 2

Wainwright & Co. maintains a buy recommendation and $25 price target for ORIC Pharmaceuticals, despite recent stock declines.
New investors are concerned about ORIC's reliance on intangibles and limited reinvestment opportunities, leading to stock price drops.
Disappointing early-stage prostate-cancer trial results have caused a significant decline in ORIC Pharmaceuticals' stock price, with some analysts reacting negatively.

Generated by AI

Oric Pharmaceuticals

Social

Apr 2

Bullish· Apr 1

Bearish· Apr 1

Announcements· May 28

Technical Analysis· Feb 9

Regulars· Mar 16

Newcomers· Apr 2

Oric Pharma CFO sells $181k in shares

H.C. Wainwright raises ORIC Pharmaceuticals price target to $27 on pipeline progress

Tracking Ole Andreas Halvorsen’s Viking Global Portfolio – Q1 2026 Update

ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen Bull Case (NASDAQ:ORIC)

ORIC Pharmaceuticals initiates phase 3 prostate cancer trial

Also Discussed

Oric Pharmaceuticals, Inc.

Company Information

Location

Oric Pharma CFO sells $181k in shares

H.C. Wainwright raises ORIC Pharmaceuticals price target to $27 on pipeline progress

Tracking Ole Andreas Halvorsen’s Viking Global Portfolio – Q1 2026 Update

ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen Bull Case (NASDAQ:ORIC)

ORIC Pharmaceuticals initiates phase 3 prostate cancer trial

Also Discussed

Social

Apr 2

Bullish· Apr 1

Bearish· Apr 1

Announcements· May 28

Technical Analysis· Feb 9

Regulars· Mar 16

Newcomers· Apr 2